Table 2.
Patient characteristics in the intent-to-treat population of ramucirumab double-blind randomized controlled phase III clinical trials
| REGARD |
RAINBOW |
REVEL |
RAISE |
REACH |
ROSE |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RAM n = 238 | Control n = 117 | RAM n = 330 | Control n = 335 | RAM n = 628 | Control n = 625 | RAM n = 536 | Control n = 536 | RAM n = 283 | Control n = 282 | RAM n = 759 | Control n = 385 | |
| Median age, years (range) | 60 (30–86) | 60 (24–87) | 61 (25–83) | 61 (24–84) | 62 (21–85) | 61 (25–86) | 62 (21–83) | 62 (33–87) | 64 (28–87) | 62 (25–85) | 54 (24–82) | 54 (29–81) |
| <65, n (%) | 156 (66) | 71 (61) | 204 (62) | 212 (63) | 391 (62) | 407 (65) | 324 (60) | 321 (60) | 150 (53) | 162 (57) | 629 (83) | 325 (84) |
| ≥65, n (%) | 82 (34) | 46 (39) | 126 (38) | 123 (37) | 237 (38) | 218 (35) | 212 (40) | 215 (40) | 133 (47) | 120 (43) | 130 (17) | 60 (16) |
| Gender, n (%) | ||||||||||||
| Male | 169 (71) | 79 (68) | 229 (69) | 243 (73) | 419 (67) | 415 (66) | 289 (54) | 326 (61) | 236 (83) | 242 (86) | 0 (0) | 0 (0) |
| Female | 69 (29) | 38 (32) | 101 (31) | 92 (27) | 209 (33) | 210 (34) | 247 (46) | 210 (39) | 47 (17) | 40 (14) | 759 (100) | 385 (100) |
| Race, n (%) | ||||||||||||
| White | 181 (76) | 91 (78) | 208 (63) | 199 (59) | 526 (84) | 503 (80) | 405 (76) | 410 (76) | 139 (49) | 137 (49) | 676 (89) | 341 (89) |
| Asian | 39 (16) | 17 (15) | 110 (33) | 121 (36) | 74 (12) | 86 (14) | 111 (21) | 103 (19) | 131 (46) | 135 (48) | 31 (4) | 20 (5) |
| Black | 4 (2) | 2 (2) | 6 (2) | 6 (2) | 17 (3) | 16 (3) | 14 (3) | 16 (3) | 5 (2) | 3 (1) | 27 (4) | 14 (4) |
| Other | 14 (6) | 7 (6) | 6 (2) | 9 (3) | 10 (2) | 20 (3) | 4 (1) | 2 (<1) | 8 (3) | 7 (3) | 25 (3) | 10 (3) |
| Not reported/ missing | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (<1) | 0 (0) | 2 (<1) | 5 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| ECOG PS, n (%) | ||||||||||||
| 0 | 67 (28) | 31 (26) | 117 (35) | 144 (43) | 207 (33) | 199 (32) | 263 (49) | 259 (48) | 159 (56) | 153 (54) | 439 (58) | 240 (62) |
| 1 | 171 (72) | 85 (73) | 213 (65) | 191 (57) | 420 (67) | 425 (68) | 268 (50) | 273 (51) | 124 (44) | 129 (46) | 318 (42) | 143 (37) |
| 2 or 3 | 0 (0) | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (<1) | 2 (<1) | 0 (0) | 0 (0) | 2 (<1) | 2 (<1) |
| Missing | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (<1) | 1 (<1) | 4 (1) | 2 (<1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
ECOG PS, Eastern Cooperative Oncology Group Performance Status; RAM, ramucirumab.